Jazz Pharmaceuticals plc (JAZZ) — Stock Score Summary

Jazz Pharmaceuticals plc (JAZZ) has a MoatMap StockRank of 92/100 based on Quality (56/100), Value (40/100), and Momentum (82/100) factor scores. The current signal is STRONG BUY. While Jazz Pharmaceuticals possesses a solid portfolio in sleep medicine and oncology, it lacks direct exposure to our high-conviction CDMO pricing power theme and faces ongoing generic erosion risks for its legacy products, failing our quality compounder hurdle.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing innovative medicines for serious diseases, particularly in neuroscience and oncology. It possesses a pipeline of proprietary drugs often addressing unmet medical needs, backed by strong R&D capabilities and a specialized sales force. The company focuses on niche therapeutic areas and uses strategic acquisitions to expand its portfolio, aiming to deliver meaningful innovation to patients.

Key Financial Metrics

Price$240.06
Market Cap$14.8B
P/E (TTM)2000.50
P/E (Forward)9.33
Price/Book3.32
Return on Equity0.7%
Return on Invested Capital-4.6%
Debt/Equity119.52
Gross Margin91.5%
Operating Margin23.5%
Revenue Growth19.1%
Free Cash Flow$1.3B

Jazz Pharmaceuticals plc operates in the Biotechnology industry, part of the Healthcare sector (Ireland).

Frequently Asked Questions

What is Jazz Pharmaceuticals plc’s (JAZZ) StockRank?
MoatMap’s StockRank for Jazz Pharmaceuticals plc (JAZZ) is 92/100, with a Strong Buy signal. It is a composite of Quality (56), Value (40), and Momentum (82) factor ranks across MoatMap’s 19,000+ stock universe.
Does Jazz Pharmaceuticals plc have an economic moat?
Jazz Pharmaceuticals plc (JAZZ) has a Quality factor score of 56/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jazz Pharmaceuticals plc a buy, hold, or sell?
MoatMap’s current signal for Jazz Pharmaceuticals plc (JAZZ) is Strong Buy, based on a StockRank of 92/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc (JAZZ) operates in the Healthcare sector, specifically the Biotechnology industry (Ireland).
Browse all ranked stocksJAZZ deep dive reportAI ChampionsHow we score stocksSense-check another stock